MARKET

CANF

CANF

Can Fite Biophar
AMEX
0.8400
+0.0069
+0.83%
Closed 15:59 12/02 EST
OPEN
0.8200
PREV CLOSE
0.8330
HIGH
0.8400
LOW
0.8200
VOLUME
10.22K
TURNOVER
4.05K
52 WEEK HIGH
2.600
52 WEEK LOW
0.6900
MARKET CAP
22.84M
P/E (TTM)
-1.4815
1D
5D
1M
3M
1Y
5Y
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel, November 25, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced fina...
Business Wire · 11/25 12:00
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Zacks · 11/10 19:13
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Zacks · 11/04 14:54
BRIEF-Can-Fite Positive New Data From It's Phase III Psoriasis Study Will Be Presented At An Industry Expert Summit
Reuters · 11/02 11:36
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
By Mark Gilman, Benzinga
News Direct · 10/31 13:15
Can-Fite Highlights Poster To Be Presented At AASLD Event Nov. 7
Benzinga · 10/25 11:15
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
PETACH TIKVA, Israel, October 25, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that ...
Business Wire · 10/25 11:00
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
PETACH TIKVA, Israel, October 13, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today the C...
Business Wire · 10/13 11:00
More
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers kinds of Can Fite Biopharma Ltd stock information, including AMEX:CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.